AIM
EW icon

Acrospire Investment Management’s Edwards Lifesciences EW Stock Holding History

Acrospire Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,400
Closed -$95K – 488
2017
Q2 		$95K Buy
2,400
+1,500
+167% +$54.8K 0.09% 280
2017
Q1 		$28K Buy
+900
New +$28.2K 0.02% 1397
2016
Q3 		– Sell
-1,200
Closed -$40K – 2021
2016
Q2 		$40K Sell
1,200
-900
-43% -$30.8K 0.03% 1216
2016
Q1 		$62K Buy
+2,100
New +$57.9K 0.04% 737

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Acrospire Investment Management's EW Position: Q3 2017 in Review

Acrospire Investment Management sold out of Edwards Lifesciences (EW) in Q3 2017, closing a stake of 2,400 shares — an estimated $95K sold.

Acrospire Investment Management first reported a position in EW in Q1 2016 and held it in 4 quarters. The position peaked at $95K in Q2 2017. 739 funds tracked by Wall St. Rank hold EW as of Q3 2017.

  • Acrospire Investment Management reported no remaining Edwards Lifesciences position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2,400 Edwards Lifesciences shares in Q3 2017, an estimated $95K.
  • Acrospire Investment Management first reported a position in Edwards Lifesciences in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Edwards Lifesciences position peaked at $95K in Q2 2017.
  • 739 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.